Status:
UNKNOWN
Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Lead Sponsor:
Assiut University
Conditions:
Behçet Disease
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of the study is to determine whether plasma levels of the soluble urokinase plasminogen activator(suPAR) can serve as a blood-based biomarker for diagnosis of Behçet's disease and its corr...
Detailed Description
Behçet's disease (BD) is a chronic, systemic vasculitis disease that can be evident in many systems and characterized by recurrent attacks, oral and/or genital aphthous ulcers, skin lesions, and infla...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Patients diagnosed as Behçet's disease according to international study group criteria (ICBD ) for diagnosis of Behçet's
Exclusion
- Age\< 18 years
- Other autoimmune diseases.
- Pregnancy.
- Acute and chronic systemic infection history.
- The presence of chronic diseases such as chronic renal failure, liver and cardiac failure.
- Presence or history of cancer.
Key Trial Info
Start Date :
July 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04105439
Start Date
July 1 2021
End Date
December 1 2021
Last Update
January 13 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.